Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAC Trial
NCT05358535Phase 3Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of propofol and etomidate (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoints: Time weighted average mean arterial pressure, Average vasopressor use and 10 more. Started Sep 2022; status: recruiting.
02
Drugs
propofoletomidate
Beyond the preview
Go deeper on NCT05358535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358535.